UY28139A1 - Compuestos quimicos - Google Patents

Compuestos quimicos

Info

Publication number
UY28139A1
UY28139A1 UY28139A UY28139A UY28139A1 UY 28139 A1 UY28139 A1 UY 28139A1 UY 28139 A UY28139 A UY 28139A UY 28139 A UY28139 A UY 28139A UY 28139 A1 UY28139 A1 UY 28139A1
Authority
UY
Uruguay
Prior art keywords
chemical compounds
compounds
warm
compositions
preparing
Prior art date
Application number
UY28139A
Other languages
English (en)
Inventor
Howard Tucker
Alan Faull
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0203821A external-priority patent/SE0203821D0/xx
Priority claimed from SE0300499A external-priority patent/SE0300499D0/xx
Priority claimed from SE0301425A external-priority patent/SE0301425D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY28139A1 publication Critical patent/UY28139A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Compuestos de fórmula (I): en donde R1, R2, R3, R4, A,X, m y n son tal como se definen; las composiciones que los comprenden, procesos para prepararlos y su uso en terapia médica (por ejemplo modulación de la actividad del receptor de CCR5 en un animal de sangre caliente).
UY28139A 2002-12-20 2003-12-19 Compuestos quimicos UY28139A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0203821A SE0203821D0 (sv) 2002-12-20 2002-12-20 Chemical Compounds
SE0300499A SE0300499D0 (sv) 2003-02-24 2003-02-24 Chemical compounds
SE0301425A SE0301425D0 (sv) 2003-05-15 2003-05-15 Chemical compounds

Publications (1)

Publication Number Publication Date
UY28139A1 true UY28139A1 (es) 2004-07-30

Family

ID=32685861

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28139A UY28139A1 (es) 2002-12-20 2003-12-19 Compuestos quimicos

Country Status (17)

Country Link
US (1) US20060189650A1 (es)
EP (1) EP1572650A1 (es)
JP (1) JP2006514107A (es)
KR (1) KR20050084424A (es)
AR (1) AR042628A1 (es)
AU (1) AU2003288856B2 (es)
BR (1) BR0317459A (es)
CA (1) CA2508624A1 (es)
CL (1) CL2003002678A1 (es)
CO (1) CO5570665A2 (es)
IS (1) IS7942A (es)
MX (1) MXPA05006381A (es)
NZ (1) NZ540780A (es)
PL (1) PL377768A1 (es)
TW (1) TW200505856A (es)
UY (1) UY28139A1 (es)
WO (1) WO2004056773A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0301369D0 (sv) * 2003-05-09 2003-05-09 Astrazeneca Ab Chemical compounds
SE0302090D0 (sv) * 2003-07-16 2003-07-16 Astrazeneca Ab Chemical compounds
ES2285485T3 (es) * 2003-07-31 2007-11-16 Astrazeneca Ab Derivados de piperidina como moduladores del receptor ccr5.
TW200610761A (en) 2004-04-23 2006-04-01 Astrazeneca Ab Chemical compounds
PT1761542E (pt) 2004-06-09 2008-03-26 Hoffmann La Roche Derivados de octa-hidro-pirrolo[3,4-c) pirrole e o seu uso com agentes antivirais
SE0401657D0 (sv) * 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
SE0401656D0 (sv) * 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
US7665658B2 (en) 2005-06-07 2010-02-23 First Data Corporation Dynamic aggregation of payment transactions
EP1940781A1 (en) 2005-10-19 2008-07-09 F.Hoffmann-La Roche Ag Phenyl-acetamide nnrt inhibitors
MX2009001198A (es) 2006-08-16 2009-02-11 Hoffmann La Roche Inhibidores no nucleosidicos de la transcriptasa inversa.
CA2664364A1 (en) * 2006-09-28 2008-04-03 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors
WO2008071587A2 (en) 2006-12-13 2008-06-19 F. Hoffmann-La Roche Ag 2-(piperidin-4-yl)-4-phenoxy- or phenylamino-pyrimidine derivatives as non-nucleoside reverse transcriptase inhibitors
UY33110A (es) 2009-12-23 2011-07-29 Ironwood Pharmaceuticals Inc Moduladores de CRTH2
WO2012009137A1 (en) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Crth2 modulators
WO2012009134A1 (en) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Crth2 modulators
WO2018068296A1 (en) 2016-10-14 2018-04-19 Merck Sharp & Dohme Corp. PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
CN113444065A (zh) * 2021-06-29 2021-09-28 浙江得乐康食品股份有限公司 一种莽草酸磺化物及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9100513A (es) * 1990-08-06 1992-04-01 Smith Kline French Lab Compuestos
IL125658A0 (en) * 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
EP1013276A1 (en) * 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
AU5600100A (en) * 1999-06-11 2001-01-02 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity
GB0011838D0 (en) * 2000-05-17 2000-07-05 Astrazeneca Ab Chemical compounds
GB0013060D0 (en) * 2000-05-31 2000-07-19 Astrazeneca Ab Chemical compounds
GB0108046D0 (en) * 2001-03-30 2001-05-23 Astrazeneca Ab Chemical compounds
WO2003062224A1 (en) * 2002-01-17 2003-07-31 Eli Lilly And Company Aza-cyclic compounds as modulators of acetylcholine receptors

Also Published As

Publication number Publication date
WO2004056773A1 (en) 2004-07-08
EP1572650A1 (en) 2005-09-14
MXPA05006381A (es) 2005-08-29
AR042628A1 (es) 2005-06-29
CA2508624A1 (en) 2004-07-08
BR0317459A (pt) 2005-11-16
US20060189650A1 (en) 2006-08-24
AU2003288856B2 (en) 2006-11-16
TW200505856A (en) 2005-02-16
KR20050084424A (ko) 2005-08-26
CL2003002678A1 (es) 2005-04-22
AU2003288856A1 (en) 2004-07-14
PL377768A1 (pl) 2006-02-20
CO5570665A2 (es) 2005-10-31
JP2006514107A (ja) 2006-04-27
IS7942A (is) 2005-07-18
NZ540780A (en) 2008-04-30

Similar Documents

Publication Publication Date Title
UY28139A1 (es) Compuestos quimicos
UY28870A1 (es) Derivados heterocíclicos, composiciones y proceso de preparación
UY28572A1 (es) Compuestos novedosos
ECSP055671A (es) Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesteresa
UY29002A1 (es) Nuevos derivados de hidantoína, procesos parasu preparación, composiciones farmacéuticas que los contienen y su uso en terapia
UY29003A1 (es) Nuevos derivados de hidantoína, procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en terapia
UY29795A1 (es) Derivados de adenina, composiciones farmacéuticas que los contienen, procesos de preparación y aplicaciones
UY28731A1 (es) Compuestos quimicos
UY28946A1 (es) Compuestos de aril-y heteroaril-alquilanina que contienen pirazol, composiciones farmacéuticas que contienen los compuestos y nuevos productos químicos intermedios
AR082536A1 (es) Derivados de 5-yodo-triazol
SE0202133D0 (sv) Novel compounds
UY28510A1 (es) Compuestos quimicos
UY27109A1 (es) Derivados de quinazolona como antagonistas de receptores adrenergicos alfa-1a/b
UY29732A1 (es) Derivados de benzotiazolonas, procesos de preparación, composiciones y combinaciones que los contienen y aplicaciones
CU23282A3 (es) DERIVADOS DEL TROPANO ÃsTILES EN TERAPIA
UY29768A1 (es) Derivados de benzotiazolonas, procesos para su preparación, composiciones farmacéuticas que los contienen y aplicaciones
UY30808A1 (es) Derivados de benzotiazolonas, composiciones conteniéndolos y aplicaciones
SV2004001549A (es) Difenilazetidinonas sustituidas en anillo, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso
ECSP099394A (es) Derivados de quinuclidinol como antogonistas de receptores muscarínicos
UY30736A1 (es) Compuestos quimicos 537
ECSP077323A (es) Nuevos derivados de sulfonamida como moduladores del receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias
UY28974A1 (es) Derivados heterocíclicos de piperidina, composiciones que los contienen y procedimiento de preparación
SE0103818D0 (sv) Chemical compounds
UY29892A1 (es) Nuevos derivados de cromano, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones
SE0103819D0 (sv) Chemical compounds

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20120307